/MBX
MBX Stock - MBX Biosciences, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$30.42+6.10%
+$1.75 (+6.10%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).74
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.8%upside
Target: $34.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MBX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$30.12 – $30.72
TARGET (TP)$34.00
STOP LOSS$27.99
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.76
52W High$34.83
52W Low$4.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-68,194,000 | $-35,311,000 | $-25,161,000 |
| Net Income | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-1.85 | $-1.02 | $-0.82 |
Company Overview
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
90%
Hold / Neutral
0%
Sell / Underperform
1
10%
Analyst Consensus🟢 Bullish
9 Bullish1 Neutral/Bearish
Price Targets
$37
Average Target
↑ 20.6% Upside
Now
$18
Low
$37
Average
$50
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 4th 2025 | Goldman | Initiation | Sell | $18 |
| November 4th 2025 | TD Cowen | Initiation | Buy | - |
| October 15th 2025 | Truist | Initiation | Buy | $50 |
| August 15th 2025 | Jefferies | Resumed | Buy | $36 |
| August 5th 2025 | Mizuho | Initiation | Outperform | $38 |
| July 16th 2025 | Oppenheimer | Initiation | Outperform | $38 |
| April 10th 2025 | Citizens JMP | Initiation | Mkt Outperform | $38 |
| October 8th 2024 | Guggenheim | Initiation | Buy | $44 |
| October 8th 2024 | Stifel | Initiation | Buy | $40 |
| October 8th 2024 | Jefferies | Initiation | Buy | $35 |
| October 8th 2024 | JP Morgan | Initiation | Overweight | $30 |
Earnings History & Surprises
MBXBeat Rate
80%
Last 5 quarters
Avg Surprise
+13.8%
EPS vs Estimate
Beats / Misses
4/1
Last 12 quarters
Latest EPS
$-0.63
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q3 24
No data
Q4 24
-2.2%
$-2.78vs$-2.72
Q1 25
+20.3%
$-0.47vs$-0.59
Q2 25
+12.3%
$-0.71vs$-0.81
Q3 25
+24.7%
$-0.58vs$-0.77
Q4 25
+13.7%
$-0.63vs$-0.73
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $-0.69 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.73 | $-0.63 | +13.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.77 | $-0.58 | +24.7% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.81 | $-0.71 | +12.3% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.59 | $-0.47 | +20.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-2.72 | $-2.78 | -2.2% | ✗ MISS |
Q3 2024 | Sep 13, 2024 | — | — | — | — |
Q3 2024 | Aug 23, 2024 | — | $-11.47 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.26 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.32 | — | — |
Latest News
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50
📈 PositiveBenzinga•Dec 19, 2025, 02:44 PM•Also:
Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18
📉 NegativeBenzinga•Dec 4, 2025, 12:47 PM
Guggenheim Maintains Buy on MBX Biosciences, Lowers Price Target to $77
📈 PositiveBenzinga•Nov 10, 2025, 02:57 PM
MBX Biosciences Q3 EPS $(0.63) Beats $(0.70) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 01:14 PM
TD Cowen Initiates Coverage On MBX Biosciences with Buy Rating
📈 PositiveBenzinga•Nov 4, 2025, 12:28 PM
Truist Securities Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $50
📈 PositiveBenzinga•Oct 15, 2025, 11:37 AM
MBX Biosciences shares are trading lower after the company announced the pricing of its $199.9 million upsized public offering of 11,108055 shares at $18.00 per share.
📉 NegativeBenzinga•Sep 25, 2025, 01:12 PM
Reported Earlier, MBX Biosciences Prices Upsized Public Offering Of 11,108,055 Shares At $18.00 Per Share For $199.9M Gross Proceeds
➖ NeutralBenzinga•Sep 25, 2025, 06:44 AM
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $56
📈 PositiveBenzinga•Sep 24, 2025, 01:53 PM
Oppenheimer Maintains Outperform on MBX Biosciences, Raises Price Target to $80
📈 PositiveBenzinga•Sep 23, 2025, 05:40 PM
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $84
📈 PositiveBenzinga•Sep 23, 2025, 01:24 PM
MBX Biosciences Announces Proposed Underwritten Public Offering Of 10M Shares Of Its Common Stock
➖ NeutralBenzinga•Sep 22, 2025, 08:18 PM
MBX surges 160% on mid-stage data for hypoparathyroidism drug canvuparatide
📈 PositiveSeeking Alpha•Sep 22, 2025, 02:20 PM•Also: , ,
MBX Biosciences shares are trading higher after the company announced once-weekly Canvuparatide achieved the primary endpoint in a Phase 2 trial.
📈 PositiveBenzinga•Sep 22, 2025, 12:00 PM
MBX Biosciences Shares Resume
➖ NeutralBenzinga•Sep 22, 2025, 11:32 AM
Market-Moving News for September 22nd
➖ NeutralBenzinga•Sep 22, 2025, 11:26 AM•Also: ,
MBX Biosciences Announced Once-weekly Canvuparatide Achieved The Primary Endpoint With Statistical Significance In Its Phase 2 Avail Trial
📈 PositiveBenzinga•Sep 22, 2025, 11:03 AM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 22, 2025, 10:55 AM
MBX Biosciences To Present Data On Trial For Its Chronic Hypoparathyroidism Treatment At 8:00 AM ET Monday
➖ NeutralBenzinga•Sep 22, 2025, 09:42 AM
MBX Biosciences shares are trading higher after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism on September 22.
📈 PositiveBenzinga•Sep 19, 2025, 08:25 PM
Frequently Asked Questions about MBX
What is MBX's current stock price?
MBX Biosciences, Inc. Common Stock (MBX) is currently trading at $30.42 per share. The stock has moved +6.10% today.
What is the analyst price target for MBX?
The average analyst price target for MBX is $34.00, based on 1 analyst.
What sector is MBX Biosciences, Inc. Common Stock in?
MBX Biosciences, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MBX's market cap?
MBX Biosciences, Inc. Common Stock has a market capitalization of $1.02 billion, making it a small-cap company.
Does MBX pay dividends?
No, MBX Biosciences, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
Explore stocks similar to MBX for comparison